



# Univ.-Prof. Dr. Michael Frass



- Programmdirektionen:** Homöopathie bei malignen Erkrankungen
- Promotion:** 1978
- Facharzt datum:** 1986
- Habilitationsdatum:** 1990
- Additivfächer:** Internistische Intensivmedizin, Notarzt, ÖÄK Diplom für Homöopathie
- Forschungsschwerpunkte:** Homöopathie, Atemwegsmanagement, Sepsis, Intensivmedizin
- Publikationen:** [Pub-Med Publikationsservice](#)
- Telefon:** 40400 – 4506
- Email:** [michael.frass@meduniwien.ac.at](mailto:michael.frass@meduniwien.ac.at)
- Projekte:**
- Studie zur Überlebenszeit von TumorpatientInnen
  - Medical Student Attitude to the Introduction of Complementary Medicine into the Medical Curriculum in Israel, Austria, Great Britain, and United States

© 2010 Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I - AKH Wien

A recently performed evaluation of questionnaires (EK 513/2008) of tumor patients who have been treated by homeopathic therapy additionally to conventional therapy showed a positive result regarding subjective well-being and quality of life for patients with additive homeopathy ( $p < 0.0001$ ). This previous study has been performed with patients with various tumor stages. In a retrospective evaluation, a significant prolongation of survival could be seen.

Similarly, a prospective randomized placebo-controlled double-blind multicentric study with patients suffering from advanced cancer and low life expectancy is planned. Therefore, patients with recently diagnosed glioblastoma, metastasized sarcoma as well as with lung cancer (NSCLC Stadium IV) are enrolled. The study investigates subjective well-being as well as survival of patients with or without additive homeopathic therapy.

Following careful evaluation of history and at each follow-up, patients receive a prescription for homeopathic medication, which is forwarded to the pharmacy encoded. According to randomization, patients receive either verum or placebo.

At each follow-up, patients are completing three questionnaires each: EORTC QLQ-C30, SF-36 and an individualized questionnaire. At least two questionnaires have to be completed by the patient in

order to be included. Questionnaires are forwarded in a blind way to the statistician. As a second hypothesis, survival time is monitored.